Cutaneous melanoma is a malignancy arising from melanocytes of the skin. Incidence rates
are rising, particularly in White populations. Cutaneous melanoma is typically driven by …

Biomarkers help to inform the clinical management of patients with melanoma. For patients
with clinically localised primary melanoma, biomarkers can help to predict post-surgical …

Simple Summary More than 40% of patients initially diagnosed with 'low risk'(stage I–II)
melanoma eventually develop melanoma recurrence or die as a result of melanoma. While …

Evidence-based reductions in cancer treatment that still preserve outcomes can result in an
improved quality of life for patients and optimized healthcare resourcing. Using melanoma …

Background Patients presenting with early-stage melanoma (AJCC pT1b-pT2a) reportedly
have a relatively low risk of a positive SNB (~ 5–10%). Those patients are usually found to …

Early-stage cutaneous melanoma patients generally have a favorable prognosis, yet a
significant proportion of metastatic melanoma cases arise from this group, highlighting the …

Background: Most patients with high-risk melanomas develop metastasis within the first few
years after diagnosis. However, late recurrence of melanoma is seen in patients that …

ABSTRACT INTRODUCTION. INTRODUCTION. The incidence of thin and early-stage
melanoma is increasing in many populations, but the clinical significance of these lesions …

Background There is a need to improve risk stratification of primary cutaneous melanomas
to better guide adjuvant therapy. Taking into account that haematoxylin and eosin (HE) …

While invasive melanoma is the focus of this discussion, the incidence of non-invasive
“melanoma in situ”(MIS) also increases steadily with age but does not lead to the mortality …